Alkermes Inc. plc (ALKS) Stock Price

ALKSStock
$49.21+64.27%52W
Market Cap$8.26B
P/E34.33x
PEG Ratio1.96
Div yield
Beta0.25

ALKS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)41.38%
Price vs S&P 500 (4W)-6.28%
PEG Ratio1.96
VGM Score51.27
P/E Ratio (Annual)34.33x

ALKS Earnings Surprise History

Q2 250.68est. 0.40
Q3 250.65est. 0.39
Q4 250.48est. 0.45
Q1 260.38est. -0.04
Q2 260.70est. 0.29

ALKS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.08
4.09
4.04
3.96

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ALKSAlkermes Inc. plc
DCB$49.21
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Alkermes Inc. plc

Alkermes is a fully integrated biotechnology company specializing in pharmaceutical products for unmet medical needs through proprietary formulation technologies. The company develops products by partnering with third-party drug suppliers and licensees, providing integrated capabilities in research, development, manufacturing, and commercialization. Primary revenue comes from the U.S., with additional operations in Ireland and international markets.